European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - levofloxacin - cystic fibrosis; respiratory tract infections - antibacterials for systemic use, - quinsair is indicated for the management of chronic pulmonary infections due to pseudomonas aeruginosa in adult patients with cystic fibrosis.consideration should be given to official guidance on the appropriate use of antibacterial agents.

European Union - English - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - community-acquired infections - antibacterials for systemic use, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1).consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - triamcinolone - tablets - triamcinolone 4 mg - triamcinolone - triamcinolone - rheumatology: - active phases of systemic vasculitis: panarteritis nodosa (in patients with concomitant positive hepatitis b serology, the duration of treatment should be restricted to two weeks), polymyalgia rheumatica (pmr), pmr with giant cell arteritis, arteritis temporalis with acute visual loss;- active phases of systemic rheumatic disease: systemic lupus erythematosus, mixed connective tissue disease;- severe progressive forms of active rheumatoid arthritis, e.g. rapidly destructive forms and/or with extra-articular manifestations;- other forms of inflammatory rheumatic arthritis, provided that the severity of symptoms requires it and non-steroidal anti-inflammatory drugs (nsaids) cannot be used:spondylarthritis (ankylosing spondylitis with involvement of peripheral joints, psoriatic arthritis, enteropathic arthropathy with high inflammatory activity);- reactive forms of arthritis;- arthritis in sarcoidosis;- severe systemic form of juvenile idiopathic arthritis (still’s disease) or with iridocyclitis refractory to topical treatment.pulmonary and respiratory tract disorders: - bronchial asthma:for the long-term treatment of severe chronic asthma (category 4) and for treatment of exacerbations in adults and children.- chronic obstructive pulmonary disease (copd):for short-term treatment (max. 14 days) of exacerbations;- upper respiratory tract disorders:for short-term treatment of severe forms of allergic rhinitis in adults after failure of all other treatment alternatives, including topical glucocorticoids.dermatology: - oral initial treatment of extensive, severe, acute skin conditions responsive to glucocorticoids, such as: allergic skin disease (e.g. acute urticaria, contact dermatitis, drug eruption), atopic eczema (acute exacerbations or extensive weeping eczema), pemphigus vulgaris.nephrology: - minimal change glomerulonephritis;- extracapillary proliferative glomerulonephritis (rapidly progressive glomerulonephritis), generally in combination with cytostatics, tapering and ending treatment in goodpasture’s syndrome; for all other forms, long-term continuation of treatment;- idiopathic retroperitoneal fibrosis.

Israel - English - Ministry of Health

bioavenir ltd, israel - ciprofloxacin - solution for infusion - ciprofloxacin 200 mg / 100 ml - ciprofloxacin - ciprofloxacin - * adults :broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens.* children and adolescents:• broncho-pulmonary infections in cystic fibrosis caused by pseudomonas aeruginosa• complicated urinary tract infections and pyelonephritis• inhalation anthrax (post-exposure prophylaxis and curative treatment)ciprofloxacin may also be used to treat severe infections in children and adolescents when there is no otheralternative .treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents

Israel - English - Ministry of Health

sanofi israel ltd - levofloxacin as hemihydrate - film coated tablets - levofloxacin as hemihydrate 500 mg - levofloxacin - levofloxacin - tavanic tablets 500 mg is indicated in adults for the treatment of the following infections:- acute pyelonephritis and complicated urinary tract infections - chronic bacterial prostatitisin the below-mentioned infections, tavanic should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections.- acute bacterial sinusitis - acute exacerbations of chronic obstructive pulmonary disease including bronchitis - community-acquired pneumonia- complicated skin and soft tissue infections.tavanic may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - film coated tablets - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections in patients of 18 years and older• respiratory infections : - uncomplicated acute bacterial sinusitis (abs) - acute exacerbations of chronic bronchitis (aecb) megaxin tablets should be used to treat adequately diagnosed abs and aecb only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed to resolve the infection. - community acquired pneumonia, except severe cases. megaxin tablets should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of this infection. • community-acquired spontaneous and wound infections of the skin and skin structure.appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin tablets may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - film coated tablets - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections in patients of 18 years and older• respiratory infections : - uncomplicated acute bacterial sinusitis (abs) - acute exacerbations of chronic bronchitis (aecb) megaxin tablets should be used to treat adequately diagnosed abs and aecb only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed to resolve the infection. - community acquired pneumonia, except severe cases. megaxin tablets should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of this infection. • community-acquired spontaneous and wound infections of the skin and skin structure.appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin tablets may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

novartis israel ltd - moxifloxacin as hydrochloride - ophthalmic solution - moxifloxacin as hydrochloride 0.5 % - moxifloxacin - moxifloxacin - for the treatment of bacterial conjunctivitis caused by susceptible strains or organisms.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - ofloxacin - ophthalmic solution - ofloxacin 0.3 % - ofloxacin - ofloxacin - for the treatment of external ocular infections caused by ofloxacin sensitive organisms.

European Union - English - EMA (European Medicines Agency)

pfizer limited - difloxacin - antibacterials for systemic use, antiinfectives for systemic use - turkeys; dogs; cattle; chicken - chickens:for the treatment of chronic respiratory infections caused by sensitive strains of escherichia coli and mycoplasma gallisepticum.turkeys:for the treatment of chronic respiratory infections caused by sensitive strains of escherichia coli and mycoplasma gallisepticum.also for the treatment of infections caused by pasteurella multocida.dogs:for the treatment of acute uncomplicated urinary-tract infections caused by escherichia coli or staphylococcus spp. and superficial pyoderma caused by staphylococcus intermedius.cattle:for the treatment of bovine respiratory disease (shipping fever, calf pneumonia) caused by single or mixed infections with pasteurella haemolytica, pasteurella multocida and / or mycoplasma spp.